BACKGROUND: Progressive supranuclear palsy (PSP) is a neurodegenerative disease without approved therapies, and therapeutics are often tried off-label in the hope of slowing disease progression. Results from these experiences are seldom shared, which limits evidence-based knowledge to guide future treatment decisions. OBJECTIVES: To describe an open-label experience, including safety/tolerability, and longitudinal changes in biomarkers of disease progression in PSP-Richardson's syndrome (PSP-RS) patients treated with either salsalate or young plasma and compare to natural history data from previous multicenter studies. METHODS: For 6 months, 10 PSP-RS patients received daily salsalate 2,250 mg, and 5 patients received monthly infusions of four units of young plasma. Every 3 months, clinical severity was assessed with the Progressive Supranuclear Palsy Rating Scale (PSPRS), and MRI was obtained for volumetric measurement of midbrain. A range of exploratory biomarkers, including cerebrospinal fluid levels of neurofilament light chain, were collected at baseline and 6 months. Interventional data were compared to historical PSP-RS patients from the davunetide clinical trial and the 4-Repeat Tauopathy Neuroimaging Initiative. RESULTS: Salsalate and young plasma were safe and well tolerated. PSPRS change from baseline (mean ± standard deviation [SD]) was similar in salsalate (+5.6 ± 9.6), young plasma (+5.0 ± 7.1), and historical controls (+5.6 ± 7.1), and change in midbrain volume (cm3 ± SD) did not differ between salsalate (-0.07 ± 0.03), young plasma (-0.06 ± 0.03), and historical controls (-0.06 ± 0.04). No differences were observed between groups on any exploratory endpoint. CONCLUSIONS: Neither salsalate nor young plasma had a detectable effect on disease progression in PSP-RS. Focused open-label clinical trials incorporating historical clinical, neuropsychological, fluid, and imaging biomarkers provide useful preliminary data about the promise of novel PSP-directed therapies.
BACKGROUND: Progressive supranuclear palsy (PSP) is a neurodegenerative disease without approved therapies, and therapeutics are often tried off-label in the hope of slowing disease progression. Results from these experiences are seldom shared, which limits evidence-based knowledge to guide future treatment decisions. OBJECTIVES: To describe an open-label experience, including safety/tolerability, and longitudinal changes in biomarkers of disease progression in PSP-Richardson's syndrome (PSP-RS) patients treated with either salsalate or young plasma and compare to natural history data from previous multicenter studies. METHODS: For 6 months, 10 PSP-RS patients received daily salsalate 2,250 mg, and 5 patients received monthly infusions of four units of young plasma. Every 3 months, clinical severity was assessed with the Progressive Supranuclear Palsy Rating Scale (PSPRS), and MRI was obtained for volumetric measurement of midbrain. A range of exploratory biomarkers, including cerebrospinal fluid levels of neurofilament light chain, were collected at baseline and 6 months. Interventional data were compared to historical PSP-RS patients from the davunetide clinical trial and the 4-Repeat Tauopathy Neuroimaging Initiative. RESULTS: Salsalate and young plasma were safe and well tolerated. PSPRS change from baseline (mean ± standard deviation [SD]) was similar in salsalate (+5.6 ± 9.6), young plasma (+5.0 ± 7.1), and historical controls (+5.6 ± 7.1), and change in midbrain volume (cm3 ± SD) did not differ between salsalate (-0.07 ± 0.03), young plasma (-0.06 ± 0.03), and historical controls (-0.06 ± 0.04). No differences were observed between groups on any exploratory endpoint. CONCLUSIONS: Neither salsalate nor young plasma had a detectable effect on disease progression in PSP-RS. Focused open-label clinical trials incorporating historical clinical, neuropsychological, fluid, and imaging biomarkers provide useful preliminary data about the promise of novel PSP-directed therapies.
Authors: Sang-Won Min; Seo-Hyun Cho; Yungui Zhou; Sebastian Schroeder; Vahram Haroutunian; William W Seeley; Eric J Huang; Yong Shen; Eliezer Masliah; Chandrani Mukherjee; David Meyers; Philip A Cole; Melanie Ott; Li Gan Journal: Neuron Date: 2010-09-23 Impact factor: 17.173
Authors: Adam L Boxer; Irfan Qureshi; Michael Ahlijanian; Michael Grundman; Lawrence I Golbe; Irene Litvan; Lawrence S Honig; Paul Tuite; Nikolaus R McFarland; Padraig O'Suilleabhain; Tao Xie; Giridhar S Tirucherai; Clifford Bechtold; Yvette Bordelon; David S Geldmacher; Murray Grossman; Stuart Isaacson; Theresa Zesiewicz; Tina Olsson; Kumar Kandadi Muralidharan; Danielle L Graham; John O'Gorman; Samantha Budd Haeberlein; Tien Dam Journal: Lancet Neurol Date: 2019-06 Impact factor: 44.182
Authors: Eduardo Tolosa; Irene Litvan; Günter U Höglinger; David Burn; Andrew Lees; María V Andrés; Belén Gómez-Carrillo; Teresa León; Teodoro Del Ser Journal: Mov Disord Date: 2014-02-14 Impact factor: 10.338
Authors: Sharon J Sha; Gayle K Deutsch; Lu Tian; Kara Richardson; Maria Coburn; Jennifer L Gaudioso; Tatiana Marcal; Ethan Solomon; Athanasia Boumis; Anthony Bet; Maarten Mennes; Erik van Oort; Christian F Beckmann; Steven P Braithwaite; Sam Jackson; Karoly Nikolich; Darby Stephens; Geoffrey A Kerchner; Tony Wyss-Coray Journal: JAMA Neurol Date: 2019-01-01 Impact factor: 18.302
Authors: Julio C Rojas; Jee Bang; Iryna V Lobach; Richard M Tsai; Gil D Rabinovici; Bruce L Miller; Adam L Boxer Journal: Neurology Date: 2017-12-27 Impact factor: 9.910
Authors: Günter U Höglinger; Gesine Respondek; Maria Stamelou; Carolin Kurz; Keith A Josephs; Anthony E Lang; Brit Mollenhauer; Ulrich Müller; Christer Nilsson; Jennifer L Whitwell; Thomas Arzberger; Elisabet Englund; Ellen Gelpi; Armin Giese; David J Irwin; Wassilios G Meissner; Alexander Pantelyat; Alex Rajput; John C van Swieten; Claire Troakes; Angelo Antonini; Kailash P Bhatia; Yvette Bordelon; Yaroslau Compta; Jean-Christophe Corvol; Carlo Colosimo; Dennis W Dickson; Richard Dodel; Leslie Ferguson; Murray Grossman; Jan Kassubek; Florian Krismer; Johannes Levin; Stefan Lorenzl; Huw R Morris; Peter Nestor; Wolfgang H Oertel; Werner Poewe; Gil Rabinovici; James B Rowe; Gerard D Schellenberg; Klaus Seppi; Thilo van Eimeren; Gregor K Wenning; Adam L Boxer; Lawrence I Golbe; Irene Litvan Journal: Mov Disord Date: 2017-05-03 Impact factor: 10.338
Authors: Eline A J Willemse; Ingrid S van Maurik; Betty M Tijms; Femke H Bouwman; Andreas Franke; Isabelle Hubeek; Leo Boelaarts; Jules J Claus; Esther S C Korf; Rob J van Marum; Gerwin Roks; Niki Schoonenboom; Nicolaas Verwey; Marissa D Zwan; Simone Wahl; Wiesje M van der Flier; Charlotte E Teunissen Journal: Alzheimers Dement (Amst) Date: 2018-09-12
Authors: Peter A Ljubenkov; Adam M Staffaroni; Julio C Rojas; Isabel E Allen; Ping Wang; Hilary Heuer; Anna Karydas; John Kornak; Yann Cobigo; William W Seeley; Lea T Grinberg; Salvatore Spina; Anne M Fagan; Gina Jerome; David Knopman; Brad F Boeve; Bradford C Dickerson; Joel Kramer; Bruce Miller; Adam L Boxer; Howard J Rosen Journal: Ann Clin Transl Neurol Date: 2018-09-20 Impact factor: 4.511
Authors: Maria Stamelou; Gesine Respondek; Nikolaos Giagkou; Jennifer L Whitwell; Gabor G Kovacs; Günter U Höglinger Journal: Nat Rev Neurol Date: 2021-08-23 Impact factor: 42.937
Authors: Brent Bluett; Alexander Y Pantelyat; Irene Litvan; Farwa Ali; Diana Apetauerova; Danny Bega; Lisa Bloom; James Bower; Adam L Boxer; Marian L Dale; Rohit Dhall; Antoine Duquette; Hubert H Fernandez; Jori E Fleisher; Murray Grossman; Michael Howell; Diana R Kerwin; Julie Leegwater-Kim; Christiane Lepage; Peter Alexander Ljubenkov; Martina Mancini; Nikolaus R McFarland; Paolo Moretti; Erica Myrick; Pritika Patel; Laura S Plummer; Federico Rodriguez-Porcel; Julio Rojas; Christos Sidiropoulos; Miriam Sklerov; Leonard L Sokol; Paul J Tuite; Lawren VandeVrede; Jennifer Wilhelm; Anne-Marie A Wills; Tao Xie; Lawrence I Golbe Journal: Front Neurol Date: 2021-07-01 Impact factor: 4.003